Stocktoria
Gossamer Bio, Inc. GOSS
Gossamer Bio, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | — | — | — | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M | -$234.0M | -$186.1M | -$149.0M |
| Interest expense | — | — | $13.5M | $13.9M | $19.4M | $12.7M | $1.9M | $12,000 |
| Income tax | -$88,000 | $893,000 | $0 | $0 | — | — | $0 | $0 |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M | -$243.4M | -$180.3M | -$147.0M |
| EPS (diluted) | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 | $-3.55 | $-3.29 | — |
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M | -$176.4M | -$144.8M | -$51.0M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M | -$177.9M | -$147.8M | -$54.5M |
| Cash & equivalents | $37.7M | $46.1M | $32.1M | $112.0M | $183.4M | $486.1M | $135.0M | $105.2M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M | $539.4M | $426.6M | $239.4M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M | $218.7M | $74.1M | $21.1M |
| Shareholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M | $320.7M | $352.5M | -$120.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -57.7% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.